Emerald Organic Products CEO Issues Letter to Shareholders Commenting on the Company’s Name Change, Vision, and Strategic Developments

Holbrook, New York, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Ian Parker, Chief Executive Officer of Emerald Organic Products Inc. (OTC: EMOR) (the “Company”, "Emerald Organic", or "Emerald Organic Products"), a diversified health sciences company, today issued a letter to shareholders on the Company’s website commenting on the Company’s vision, key business-building strategies and new developments serving to position itself as one of the world’s leading healthcare technology companies. The letter states, in summary:

On March 27th, 2020, Emerald Organic Products announced that it signed a Plan of Merger Agreement to acquire a 51% controlling interest in Bonsa Health, a digital pharmacy platform enabling same-day delivery of prescriptions anywhere in the United States. On  March 31st, 2020, Emerald Organic Products announced that it entered into a definitive agreement to acquire 100% of Carie Health, a leading telehealth and virtual care technology and service solutions company.

To reflect its unification and integration of Bonsa Health and Carie Health, as well as its positioning as a disruptive healthcare technology company that defragments and democratizes health and wellness through its end-to-end ecosystem, the Company is in the final stages of changing its name to Carie Health, Inc. (“Carie”). We expect our legacy consumer packaged good (“CPG”) operations to play a key role in delivering additional value to the end-users in our ecosystem.

Carie’s objective is to build, as well as acquire, technology that touches people at the most important points of their lives. This current health crisis has made the Company acutely aware that accessibility and affordability of quality healthcare and health products is not a constant in this country. Democratizing health and wellness through modernization and innovation is at the core of that objective. We believe our combination of virtual care capabilities and digital pharmacy and prescription delivery together uniquely positioned Carie to meet this demand.

Carie has entered into a Letter of Intent to acquire a network of strategically positioned pharmacies to enhance Carie’s prescription drug delivery capabilities while further defragmenting the healthcare vertical. Furthermore, Carie’s strategic acquisition target currently generates annual revenues greater than $120 million, thereby enhancing the Company’s financial position.